DOSE OF REALITY: BREAKING DOWN BIG PHARMA’S YEAR OF BAD BEHAVIOR IN 2022

12-28-2022 Blog Posts

Get the Facts on Big Pharma’s Year of Out-of-Control Launch Prices, Price Hikes, Anti-Competitive Tactics and Massive Spending on a Debunked Blame Game Despite unprecedented scrutiny of Big Pharma’s egregious pricing and anti-competitive practices and major progress in Washington toward holding the pharmaceutical industry accountable, Big Pharma continued to double down on a business-as-usual approach […]

TWO BIRDS OF A FEATHER: BIG PHARMA PRICE HIKERS TO JOIN FORCES IN LARGEST HEALTH CARE MERGER OF THE YEAR

12-13-2022 Blog Posts

Amgen and Horizon Therapeutics Eye Merger As Both Continue to Hike Prices on Blockbuster Prescription Drugs On Monday, Big Pharma giant Amgen announced plans to acquire Horizon Therapeutics for $27.8 billion, making it the largest healthcare merger of the year. Horizon Therapeutics is known for several rare autoimmune and severe inflammatory disease drugs, including Tepezza, […]

SECOND OPINION: BIG PHARMA EXEC BOOED AS HE DISMISSES AFFORDABILITY CONCERNS ON HIGH PRICED TREATMENTS AS “LUDICROUS”

12-9-2022 Blog Posts

Regeneron Co-Founder Says, “Forget About That” When Pressed on How Patients and the U.S. Health Care System Will Afford Treatments Priced in the Millions of Dollars On Wednesday, Regeneron Pharmaceuticals co-founder and Chief Scientific Officer George Yancopoulos brazenly dismissed concerns with the affordability of Big Pharma products priced in the millions of dollars during a […]

BIG PHARMA WATCH: UNJUSTIFIED PRICE HIKES ON JUST SEVEN DRUGS COST U.S. $805 MILLION IN 2021

12-7-2022 Blog Posts

Brand Name Drug Companies Continue Raising Prices on Blockbuster Products With No Increase in Clinical Value for Patients In case you missed it, the Institute for Clinical and Economic Review (ICER) released new data showing Big Pharma continues to repeatedly raise list prices on blockbuster drugs in the U.S. with no substantial increase in their clinical benefit […]

BIG PHARMA WATCH: MERCK PLOTS TO FURTHER BLOCK COMPETITION AND EXTEND MONOPOLY PRICING ON BLOCKBUSTER CANCER DRUG KEYTRUDA

12-2-2022 Blog Posts

Big Pharma Giant Wants New Patents for Formulation Changes That Won’t Improve Clinical Benefit of Cancer Drug — Adding to Existing Patent Thicket of 129 Filed Applications On Friday, Big Pharma giant Merck announced that it will seek new patents on its blockbuster cancer drug Keytruda, which last year brought in over $17 billion for […]

BIG PHARMA WATCH: DRUG COMPANY VERTEX PRICE-GOUGING BRAND NAME CYSTIC FIBROSIS TREATMENTS AND BANKING HUGE PROFITS

11-30-2022 Blog Posts

Patient Advocates Warn Access to Egregiously Priced Treatments at Risk Drug company Vertex manufacturers four key cystic fibrosis (CF) treatments, Trikafta, Symdeko, Orkambi, and Kalydeco that all carry price tags far exceeding estimates for a fair price — threatening access to these lifesaving medicines for patients. Vertex set list prices on three of the treatments […]

TWO BIRDS OF A FEATHER: BIG PHARMA COMPANIES EYE MERGER TO UNDERMINE GENERIC COMPETITION TO OPIOID TREATMENTS

11-16-2022 Blog Posts

Brand Name Drug Company to Acquire Manufacturer of Narcan as Both Work to Block Competition from More Affordable Alternatives In case you missed it, on Monday pharmaceutical company Indivior announced plans to acquire Opiant Pharmaceuticals as part of an effort to consolidate market power over opioid addiction and opioid treatments and undermine access to more […]

BIG PHARMA EARNINGS WATCH: GLAXOSMITHKLINE, AMGEN, ASTRAZENECA

11-11-2022 Blog Posts

Big Pharma Giants Notch Expectation-Busting Earnings After Continuing to Hike Drug Prices A final round of Big Pharma third quarter earnings reports from GlaxoSmithKline, Amgen and AstraZeneca showed the pharmaceutical industry continues to ride high on bigtime profits fueled by continued bigtime price-gouging. Driven by increasing revenue from pharmaceutical divisions and strong COVID-19 vaccine and […]

BIG PHARMA EARNINGS WATCH: PFIZER, ABBVIE, SANOFI, ELI LILLY

11-4-2022 Blog Posts

Big Pharma Giants Beat Wall Street Expectations After Year of Price Increases, Pfizer’s Bourla Pressed on “Sheer Magnitude” of COVID-19 Vaccine Price Hike on Earnings Call Big Pharma companies Pfizer, AbbVie, Sanofi, and Eli Lilly all topped Wall Street expectations in third quarter earnings reports this week — as all four companies continue to engage […]

BIG PHARMA WATCH: REPRESENTATIVE KATIE PORTER HIGHLIGHTS BIG PHARMA’S OUTRAGEOUS CANCER DRUG LAUNCH PRICES

11-3-2022 Blog Posts

New Report Finds Brand Name Drug Companies Increased Prices on New Oncology Treatments by 25 Percent Over Four Years This week, U.S. Representative Katie Porter (D-CA) released a report, “Skyrocketing: How Big Pharma Exploits Launch Prices to Cash in on Cancer,” investigating Big Pharma’s increasingly outrageous launch prices on new cancer drugs — and adding for […]

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.